GK01 stemness-enriched tumor-reactive T-cell therapy plus IL-2 in advanced solid tumors: ORR and clonal persistence results in a first-in-human phase I study (GUARDIAN-01). Phase 1 trial of a KRAS ...
Membership of the Immune Oncology (IO) Program is comprised of a diverse and multidisciplinary group of investigators with robust strength in immunogenetics, cellular and molecular immunology, ...
Knowledge of HPV-related penile cancer among U.S. men: Socioeconomic differences and divergence. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results